“I’m still learning how the medication affects me, and as a new patient, not only do I feel very tired and very sedated, but I’m also eating all the time,” she says. You’re going to put on that weight.” It’s just part of the coping mechanism,” he said.
Professor Ashley Bush, a researcher at Melbourne’s Florey Institute of Neuroscience and Mental Health, told SBS News she was “very excited” about the FDA’s decision to approve Cobenfi.
“I think this is encouraging. The psychiatric community is cautiously optimistic that this may be a really great new asset to add to the schizophrenia toolkit. “I think it’s encouraging for both psychiatrists and psychiatrists,” he said.
What is schizophrenia?
Symptoms of schizophrenia are usually divided into positive symptoms, such as hallucinations and delusions, and negative symptoms, such as decreased emotional expression and social withdrawal.
What drugs are used to treat schizophrenia?
Atypical antipsychotics include drugs such as clozapine and risperidone.
”[Cobenfy] “It’s much cleaner. It’s a more targeted drug,” he said.
Where does Cobenfi come from?
Although the trial that led to U.S. approval lasted just five weeks, the FDA said patients who received Cobenfi “experienced a significant reduction in symptoms” compared to those in the placebo group.
Treatment-resistant schizophrenia affects approximately one-third of people diagnosed with the condition.
When will it be available in Australia?
“It’s kind of like getting by with the diagnosis that we have…We just get through the days.”
